Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy.

What Was Tested

Researchers studied Magnesium and Cisplatin in this randomized controlled trial publication.

This study evaluated the effects of cisplatin on 18 nerve conduction parameters of median, ulnar, peroneal, and sural nerves in relation to age, magnesium nadir, average magnesium, and magnesium replacement in gynecologic oncology patients.

The patients were placed randomly on either magnesium supplementation (intravenous plus oral) or placebo.

Who Took Part

According to the abstract, 37 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The patients were allocated by chance, so the Magnesium group and the comparison group should start out alike.

Some patients received a placebo instead of Magnesium, giving a reference point.

What Was Measured

This study evaluated the effects of cisplatin on 18 nerve conduction parameters of median, ulnar, peroneal, and sural nerves in relation to age, magnesium nadir, average magnesium, and magnesium replacement in gynecologic oncology patients.

PubMed files the paper under topics including Action Potentials, Age Factors, Cisplatin, Magnesium, Median Nerve, Neural Conduction and Peripheral Nervous System Diseases.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Magnesium and Cisplatin in 37 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Gynecologic oncology), a journal based in United States.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, all human trials.